|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Deferred franchise and regional development costs, current portion | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Discontinued operations current assets ($1.0 million attributable to VIEs) | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||||
| Deferred franchise and regional development costs, net of current portion | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Deferred tax assets ($1.1 million and $1.1 million attributable to VIEs as of September 30, 2024 and December 31, 2023) | ||||||||||||||||||||
| Discontinued operations noncurrent assets ($1.1 million attributable to VIEs as of December 31, 2023) | ||||||||||||||||||||
| Deposits and other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Co-op funds liability | ||||||||||||||||||||
| Payroll liabilities | ||||||||||||||||||||
| Operating lease liability, current portion | ||||||||||||||||||||
| Finance lease liability, current portion | ||||||||||||||||||||
| Deferred franchise fee revenue, current portion | ||||||||||||||||||||
| Franchise | ||||||||||||||||||||
| Revenues from company-owned or managed clinics | ||||||||||||||||||||
| Total deferred franchise fee revenue, current portion | ||||||||||||||||||||
| Deferred revenue from company clinics ($1.6 million and $1.6 million attributable to VIEs as of March 31, 2024 and December 31, 2023) | ||||||||||||||||||||
| Upfront regional developer fees, current portion | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Discontinued operations current liabilities ($3.2 million and $6.1 million attributable to VIEs, respectively) | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Operating lease liability, net of current portion | ||||||||||||||||||||
| Finance lease liability, net of current portion | ||||||||||||||||||||
| Debt under the Credit Agreement | ||||||||||||||||||||
| Deferred franchise fee revenue, net of current portion | ||||||||||||||||||||
| Upfront regional developer fees, net of current portion | ||||||||||||||||||||
| Discontinued operations liabilities, net of current portion ($1.2 million attributable to VIEs as of December 31, 2023) | ||||||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Series A preferred stock, $0.001 par value; 50,000 shares authorized, zero shares issued and outstanding, respectively | ||||||||||||||||||||
| Common stock, $0.001 par value; 20,000,000 shares authorized, 15,755,965 shares issued and 14,199,592 shares outstanding and 15,471,715 shares issued and 14,142,626 shares outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury stock 1,556,373 shares and 1,329,089 shares, at cost, respectively | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total The Joint Corp. stockholders' equity | ||||||||||||||||||||
| Non-controlling Interest | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...